YiChang HEC ChangJiang Pharmaceutical : VOLUNTARY ANNOUNCEMENT SUBMISSION OF REGISTRATION FOR DOMESTIC PRODUCTION OF INSULIN ASPART INJECTION HAVING BEEN ACCEPTED

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

֝׹؇ජΈڗϪᖹٰุ΅Ϟࠢʮ̡

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

VOLUNTARY ANNOUNCEMENT

SUBMISSION OF REGISTRATION FOR DOMESTIC PRODUCTION OF INSULIN ASPART INJECTION

HAVING BEEN ACCEPTED

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the ''Company'', together with its subsidiaries, the ''Group'') on a voluntary basis.

The board of directors (the ''Board'') of the Company is pleased to announce that the Company has received approval notice from the National Medical Products Administration relating to registration for domestic production of Insulin Aspart Injection (the ''Product''), the Company's self-developed product, with approval number of CXSS2100025GUO. Currently, there are insulin aspart injections manufactured by two Chinese companies having received approval to launch from the National Medical Products Administration.

Insulin aspart is a kind of human insulin analog. Compared with soluble human insulin, insulin aspart has a faster onset of action after subcutaneous injection and a shorter duration of action, which can better simulate the physiological pattern of insulin secretion after eating, thereby more effectively improving postprandial glucose excursions. Since insulin aspart is convenient for diabetic patients, it is a particularly important mealtime insulin in the current diabetes treatment.

According to the data published by the International Diabetes Federation in 2019, the number of diabetics in mainland China was about 116 million, and the prevalence rate for the 20-79 age group was about 10.4%. According to data from IQVIA, the sales of drugs for diabetes segment in China in 2019 was approximately US$3.921 billion, increasing by approximately 8.97% as compared to 2018. Among them, the sales of insulin and its analogues in China accounted for approximately 42.52% of the total market share in 2019, showing a considerable market potential.

The Company has a comprehensive plan for the treatment of diabetes and a complete product line in place. References are made to the announcement of the Company dated 15 June 2020 in relation to the approval to launch the Company's recombinant human insulin injection being obtained and the commencement of market promotion of such product, and the announcements of the Company dated 16 October 2020 and 19 February 2021 in relation to the acceptance of the submission of registration for domestic production of insulin glargine injection and insulin aspart 30 injection. In the future, if the Product passes the assessment and approval process of the National Medical Products Administration and is launched in the market, the Company's product portfolio in the area of diabetes treatment will be further enriched.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

On behalf of the Board

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

TANG Xinfa

Chairman

Hubei, the PRC

1 March 2021

As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive directors.